Sisram Medical Ltd, an investment holding company, designs, develops, manufactures, and sells energy-based aesthetic medical, minimally invasive treatment systems, and non-energy based devices and cosmeceuticals in the Asia Pacific, Europe, North America, Latin America, the Middle East, and Africa.
Sisram Medical Ltd, an investment holding company, designs, develops, manufactures, and sells energy-based aesthetic medical, minimally invasive treatment systems, and non-energy based devices and cosmeceuticals in the Asia Pacific, Europe, North America, Latin America, the Middle East, and Africa. It offers products and treatments portfolio, including hair removal, skin rejuvenation, acne and acne scars, body and face contouring, pigmentation and skin resurfacing, fat grafting, dermal facial fillers, skin tissue remodelling injectables, personal care, aesthetic dentistry, trans epidermal delivery, cellulite treatment, stretch marks, vascular and pigmented lesions, hydradermabrasion, blepharoplasty-non surgical eyelid lift, liposuction, feminine health, and sexual rehabilitation. The company manufactures, distributes, and sells medical equipment.
Sisram Medical Fundamentals Summary
How do Sisram Medical's earnings and revenue compare to its market cap?
Is 1696 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6
Valuation Score 2/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Analyst Forecast
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 1696?
Other financial metrics that can be useful for relative valuation.
The above table shows the n/a ratio for 1696. This is calculated by dividing 1696's market cap by their current
preferred multiple.
What is 1696's n/a Ratio?
n/a Ratio
0x
n/a
n/a
Market Cap
US$691.08m
1696 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Price-To-Earnings vs Industry: 1696 is expensive based on its Price-To-Earnings Ratio (22.1x) compared to the Hong Kong Medical Equipment industry average (16.3x)
Price to Earnings Ratio vs Fair Ratio
What is 1696's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
1696 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio
22.1x
Fair PE Ratio
20.8x
Price-To-Earnings vs Fair Ratio: 1696 is expensive based on its Price-To-Earnings Ratio (22.1x) compared to the estimated Fair Price-To-Earnings Ratio (20.8x).
Share Price vs Fair Value
What is the Fair Price of 1696 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 1696 (HK$11.62) is trading below our estimate of fair value (HK$11.83)
Significantly Below Fair Value: 1696 is trading below fair value, but not by a significant amount.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Future Growth
How is Sisram Medical forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Future Growth Score
4/6
Future Growth Score 4/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE
22.3%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 1696's forecast earnings growth (22.3% per year) is above the savings rate (1.6%).
Earnings vs Market: 1696's earnings (22.3% per year) are forecast to grow faster than the Hong Kong market (16.8% per year).
High Growth Earnings: 1696's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 1696's revenue (17.8% per year) is forecast to grow faster than the Hong Kong market (10% per year).
High Growth Revenue: 1696's revenue (17.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 1696's Return on Equity is forecast to be low in 3 years time (12%).
Discover growth companies
Past Performance
How has Sisram Medical performed over the past 5 years?
Past Performance Score
5/6
Past Performance Score 5/6
Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE
16.8%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 1696 has high quality earnings.
Growing Profit Margin: 1696's current net profit margins (10.6%) are higher than last year (8.2%).
Past Earnings Growth Analysis
Earnings Trend: 1696's earnings have grown by 16.8% per year over the past 5 years.
Accelerating Growth: 1696's earnings growth over the past year (134.2%) exceeds its 5-year average (16.8% per year).
Earnings vs Industry: 1696 earnings growth over the past year (134.2%) exceeded the Medical Equipment industry 35.4%.
Return on Equity
High ROE: 1696's Return on Equity (8.1%) is considered low.
Discover strong past performing companies
Financial Health
How is Sisram Medical's financial position?
Financial Health Score
6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Debt Coverage
Interest Coverage
Financial Position Analysis
Short Term Liabilities: 1696's short term assets ($297.6M) exceed its short term liabilities ($83.6M).
Long Term Liabilities: 1696's short term assets ($297.6M) exceed its long term liabilities ($43.0M).
Debt to Equity History and Analysis
Debt Level: 1696 has more cash than its total debt.
Reducing Debt: 1696's debt to equity ratio has reduced from 492.5% to 1.8% over the past 5 years.
Debt Coverage: 1696's debt is well covered by operating cash flow (443.9%).
Interest Coverage: 1696's interest payments on its debt are well covered by EBIT (29.2x coverage).
Balance Sheet
Discover healthy companies
Dividend
What is Sisram Medical current dividend yield, its reliability and sustainability?
Dividend Score
0/6
Dividend Score 0/6
Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Cash Flow Coverage
1.35%
Current Dividend Yield
Upcoming Dividend Payment
Dividend Yield vs Market
Notable Dividend: 1696's dividend (1.35%) isn’t notable compared to the bottom 25% of dividend payers in the Hong Kong market (2.87%).
High Dividend: 1696's dividend (1.35%) is low compared to the top 25% of dividend payers in the Hong Kong market (8.31%).
Stability and Growth of Payments
Stable Dividend: 1696 is not paying a notable dividend for the Hong Kong market, therefore no need to check if payments are stable.
Growing Dividend: 1696 is not paying a notable dividend for the Hong Kong market, therefore no need to check if payments are increasing.
Earnings Payout to Shareholders
Earnings Coverage: 1696 is not paying a notable dividend for the Hong Kong market.
Cash Payout to Shareholders
Cash Flow Coverage: 1696 is not paying a notable dividend for the Hong Kong market.
Discover strong dividend paying companies
Management
How experienced are the management team and are they aligned to shareholders interests?
4.0yrs
Average management tenure
CEO
Lior Dayan (52 yo)
5.17yrs
Tenure
US$1,592,000
Compensation
Mr. Lior Moshe Dayan has been Chief Executive Officer and Executive Director at Sisram Medical Ltd since June 6, 2017 and is responsible for its overall and day-to-day management and development. Mr. Dayan...
CEO Compensation Analysis
Compensation vs Market: Lior's total compensation ($USD1.59M) is above average for companies of similar size in the Hong Kong market ($USD548.44K).
Compensation vs Earnings: Lior's compensation has increased by more than 20% in the past year.
Leadership Team
Experienced Management: 1696's management team is considered experienced (4 years average tenure).
Board Members
Experienced Board: 1696's board of directors are considered experienced (5 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Sisram Medical Ltd's employee growth, exchange listings and data sources
All financial data provided by Standard & Poor's Capital IQ.
Data
Last Updated (UTC time)
Company Analysis
2022/08/16 00:00
End of Day Share Price
2022/08/16 00:00
Earnings
2021/12/31
Annual Earnings
2021/12/31
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.